While the biotechnology industry continues to debate whether the window for initial public offerings is closing, two drug developers priced IPOs during a US stock trading week shortened by the July 4th holiday and six revealed their plans to become public companies.
It appears that small biotechs, including companies that only recently began to make a name for themselves among private investors,...